China: Domestic drug firms fined for price fixing

China’s anti-monopoly regulator has fined five domestic drug firms a total of close to $607,977 for fixing the prices of their medicines, the watchdog said on Tuesday, as the country battles to keep medicine prices down.

The drug firms colluded over a period from April 2014 to September 2015 to raise the price of allopurinol tablets, a drug used to treat gout and kidney disease, the National Development and Reform Commission said in statements on its website.

The fine, though relatively small, indicates China’s anti-trust watchdogs may be turning attention towards medicines, a potential headache for domestic and international firms targeting the world’s second-largest pharmaceutical market.

“(The firms) created monopolies by agreeing to raise sales prices and to artificially carve up the market,” the NDRC said in the statements. It added the drug was commonly used and was on the country’s essential drug list.

“This eliminated or restricted market competition, raising the cost of allopurinol tablets for the end user, and so harmed the interests of consumers.”

Full content: Reuters

Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.